Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | QDPR | P09417 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21361657 | 0.82 | SIGMAR1 (0.52) | SIGMAR1HTR2CQDPR | |
| SCHEMBL604266 | 0.77 | TYMP (0.40) | TYMP | |
| SCHEMBL15048839 | 0.77 | TYMP (0.40) | TYMP | |
| SCHEMBL11246723 | 0.76 | SIGMAR1 (0.50) | SIGMAR1HTR2CQDPR | |
| SCHEMBL9212418 | 0.74 | SIGMAR1 (0.39) | TYMPSIGMAR1HTR2CQDPR | |
| SCHEMBL28649782 | 0.72 | — | — | |
| SCHEMBL1109730 | 0.72 | TYMP (0.41) | TYMP | |
| SCHEMBL3343472 | 0.72 | — | — | |
| SCHEMBL5136081 | 0.69 | — | — | |
| SCHEMBL5960583 | 0.69 | TYMP (0.39) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646659-B1 | METHOD FOR THE PREPARATION OF 1,3-PROPANE DISULFONIC ACID COMPOUNDS | KIACTA S RL (CH) | 2014-05-14 | — | — | EP | disclosed |
| US-20110021813-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | KONG XIANQI | 2011-01-27 | — | — | US | disclosed |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-31 | — | — | US | disclosed |
| US-7253306-B2 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-07 | — | — | US | disclosed |
| EP-1646659-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | Neurochem (International) Limited (CH) | 2006-04-19 | — | — | EP | disclosed |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-06-30 | — | — | US | disclosed |
| WO-2004113391-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021813-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | MPST, TTR, STS | TYMP 1376/4885SIGMAR1 3298/4885HTR2C 4058/4885 |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | MPST, TTR, STS | TYMP 1376/4885SIGMAR1 3298/4885HTR2C 4058/4885 |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | MPST, TTR, STS | TYMP 1376/4885SIGMAR1 3298/4885HTR2C 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.